Sponsor: Genelux Corporation
Sponsor Study ID: 01182022GNLX
Study Title: GOG-3076 a Phase 3 Trial in Platinum-Resistant/Refractory Ovarian Cancer
CTO #: 103683
NCT Number: NCT05281471
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Ovary
Study Objectives: The primary objective is to determine Progression-free Survival (PFS) by RECIST 1.1. To determine Objective Response Rate (ORR) and Duration of Response (DOR) by RECIST 1.1, PFS by RECIST 1.1 (in modified population), PFS by iRECIST, Overall Survival (OS), and safety.